Recombinant Proteins Industry Size

The report "Recombinant Proteins Market by Product (Growth Factors, Chemokines, Membrane Proteins, Receptors), Host Cell (Mammalian, Insect, Yeast), Application (Drug Discovery, Development [Biologics, CGT, Vaccines], Research, Production)- Global Forecast to 2031" is expected to reach USD 3.90 billion in 2031 from USD 2.63 billion in 2026, at a CAGR of 8.2% during the forecast period.

Browse 432 market data Tables and 43 Figures spread through 408 Pages and in-depth TOC on "Recombinant Proteins Market by Product (Growth Factors, Chemokines, Membrane Proteins, Receptors), Host Cell (Mammalian, Insect, Yeast), Application (Drug Discovery, Development [Biologics, CGT, Vaccines], Research, Production)- Global Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/recombinant-proteins-market-70095015.html

The recombinant proteins market is experiencing significant growth, driven by the expanding pipeline of recombinant therapeutics, increasing demand for biologics, and wider applications in drug discovery and development. Advances in protein engineering, mammalian expression systems, and purification technologies are improving protein yield, stability, biological activity, and manufacturing scalability. Pharmaceutical and biotechnology companies are increasingly using recombinant proteins for target identification, functional assays, vaccine development, diagnostics, and cell and gene therapy research. Growing investments in biopharmaceutical production and demand for engineered, high-purity proteins are further supporting market expansion. However, the market continues to face challenges such as high production costs, lot-to-lot variability, protein instability, complex expression and purification processes, and stringent quality requirements.

By product, growth factors and chemokines held the largest share of the recombinant proteins market in 2025.

By product, the recombinant proteins market includes growth factors and chemokines, immune response proteins, structural proteins, membrane proteins, kinase proteins, regulatory proteins, recombinant metabolic enzymes, adhesion molecules and receptors, and other recombinant proteins. In 2025, growth factors and chemokines accounted for the largest market share, driven by their extensive use in cell proliferation, differentiation, migration, and immune signaling. These proteins are widely used in drug discovery, stem cell research, cancer biology, regenerative medicine, and cell and gene therapy development. Increasing demand for cytokines, fibroblast growth factors, epidermal growth factors, and other signaling proteins in cell culture and biologics research further supports the category's leading position.

By host cell, mammalian cells are expected to grow at the highest CAGR during the forecast period.

By host cell, the recombinant proteins market is categorized into mammalian cells, insect cells, yeast and fungi, bacterial cells, and other host cells. Mammalian cells are expected to grow at the highest CAGR during the forecast period because of their ability to produce complex recombinant proteins with appropriate folding and post-translational modifications. These systems, particularly Chinese hamster ovary (CHO) and human embryonic kidney (HEK) cells, are widely used to produce therapeutic proteins that require high biological activity and structural consistency. The expanding pipeline of recombinant therapeutics, increasing demand for complex biologics, and advances in cell-line engineering and expression technologies are expected to accelerate the adoption of mammalian expression systems.

By region, Asia Pacific is expected to grow at the highest CAGR during the forecast period.

Asia Pacific is expected to grow at the highest CAGR in the recombinant proteins market, driven by expanding pharmaceutical and biotechnology industries, increasing investments in biopharmaceutical manufacturing, and growing research activity across the region. Countries such as China, India, Japan, and South Korea are strengthening their capabilities in biologics development, recombinant protein production, and life sciences research. Rising demand for recombinant proteins in drug discovery, vaccine development, diagnostics, and cell culture, alongside the expansion of contract development and manufacturing organizations, is creating growth opportunities. Additionally, government initiatives supporting biotechnology innovation, increasing research collaborations, and investments in advanced protein expression and purification technologies are expected to accelerate regional market growth.

Some of the leading players in the market include Bio-Techne (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Abnova Corporation (Taiwan), Bio-Rad Laboratories, Inc. (US), BPS Bioscience, Inc. (US), Sino Biological, Inc. (China), GenScript (China), and Revvity (US), among others.

Don’t miss out on business opportunities in Recombinant Proteins Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com